Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mustafa Khasraw

Showing results (151-160 of 176) with videos related to

Pageof 18
Sort By:
BMJ Open|May 15, 2023
LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot studyBenjamin Y Kong, Hao-Wen Sim, Anna K Nowak, et al.
International Journal of Cancer|June 21, 2018
Profiles of brain metastases: Prioritization of therapeutic targetsSherise D Ferguson, Siyuan Zheng, Joanne Xiu, et al.
Nature Cancer|June 12, 2025
A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trialEric M Thompson, David M Ashley, Katayoun Ayasoufi, et al.
Neuro-Oncology Advances|May 25, 2022
Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent <i>IDH</i> wild-type glioblastomaJohn F de Groot, Albert H Kim, Sujit Prabhu, et al.
Neuro-Oncology Advances|February 23, 2023
Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastomaBenedito A Carneiro, Kyriakos P Papadopoulos, John H Strickler, et al.
Neuro-Oncology|April 14, 2022
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trialAntonio Omuro, Alba A Brandes, Antoine F Carpentier, et al.
Nature Communications|January 14, 2021
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapyMatthias Gromeier, Michael C Brown, Gao Zhang, et al.
Neuroendocrinology|July 11, 2018
Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine TumoursEric Raymond, Matthew H Kulke, Shukui Qin, et al.
BMJ Open|August 4, 2023
[<sup>18</sup>F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trialEng-Siew Koh, Hui K Gan, Clare Senko, et al.
Neuro-Oncology Advances|October 16, 2023
NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastomaHao-Wen Sim, Luke Wachsmuth, Elizabeth H Barnes, et al.
Pageof 18

Showing results (151-160 of 176) with videos related to

Sort By:
Pageof 18
BMJ Open|May 15, 2023
LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot studyBenjamin Y Kong, Hao-Wen Sim, Anna K Nowak, et al.
International Journal of Cancer|June 21, 2018
Profiles of brain metastases: Prioritization of therapeutic targetsSherise D Ferguson, Siyuan Zheng, Joanne Xiu, et al.
Nature Cancer|June 12, 2025
A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trialEric M Thompson, David M Ashley, Katayoun Ayasoufi, et al.
Neuro-Oncology Advances|May 25, 2022
Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent <i>IDH</i> wild-type glioblastomaJohn F de Groot, Albert H Kim, Sujit Prabhu, et al.
Neuro-Oncology Advances|February 23, 2023
Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastomaBenedito A Carneiro, Kyriakos P Papadopoulos, John H Strickler, et al.
Neuro-Oncology|April 14, 2022
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trialAntonio Omuro, Alba A Brandes, Antoine F Carpentier, et al.
Nature Communications|January 14, 2021
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapyMatthias Gromeier, Michael C Brown, Gao Zhang, et al.
Neuroendocrinology|July 11, 2018
Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine TumoursEric Raymond, Matthew H Kulke, Shukui Qin, et al.
BMJ Open|August 4, 2023
[<sup>18</sup>F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trialEng-Siew Koh, Hui K Gan, Clare Senko, et al.
Neuro-Oncology Advances|October 16, 2023
NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastomaHao-Wen Sim, Luke Wachsmuth, Elizabeth H Barnes, et al.
Pageof 18